At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Squamous Cell Non-small Cell Lung Cancer. Completed, enrolled 117 participants across 33 sites in 4 countries.
Detailed Summary
The purpose of the study is to assess the objective response rate (change in tumor size from baseline) in patients with advanced or metastatic squamous cell nonsmall-cell lung cancer treated with Nivolumab (BMS-936558) after failure of 2 prior systemic regimens
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSquamous Cell Non-small Cell Lung Cancer
CountriesFrance, Germany, Italy, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartNov 2012
Primary CompletionJan 2014
Study CompletionApr 2021
TodayJul 2026
First PostedNov 6, 2012
Enrollment StartNov 16, 2012
Primary CompletionJan 22, 2014
Study CompletionApr 22, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.7 years ago
Interventions
Nivolumabdrug